SG11201608441YA - Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect - Google Patents
Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effectInfo
- Publication number
- SG11201608441YA SG11201608441YA SG11201608441YA SG11201608441YA SG11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- salt
- treatment
- pharmaceutical composition
- composition containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014129740 | 2014-06-24 | ||
| JP2015024785 | 2015-02-10 | ||
| PCT/JP2015/068218 WO2015199136A1 (en) | 2014-06-24 | 2015-06-24 | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608441YA true SG11201608441YA (en) | 2016-11-29 |
Family
ID=54938214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608441YA SG11201608441YA (en) | 2014-06-24 | 2015-06-24 | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9963456B2 (en) |
| EP (1) | EP3103802B1 (en) |
| JP (1) | JP6192741B2 (en) |
| KR (1) | KR101947289B1 (en) |
| CN (1) | CN106661031B (en) |
| AU (1) | AU2015281155B9 (en) |
| BR (1) | BR112016025835B1 (en) |
| CA (1) | CA2946833C (en) |
| DK (1) | DK3103802T3 (en) |
| ES (1) | ES2656772T3 (en) |
| HU (1) | HUE037266T2 (en) |
| MX (1) | MX2016015015A (en) |
| MY (1) | MY183327A (en) |
| NO (1) | NO3103802T3 (en) |
| PH (1) | PH12016502130A1 (en) |
| PL (1) | PL3103802T3 (en) |
| PT (1) | PT3103802T (en) |
| RU (1) | RU2658008C2 (en) |
| SG (1) | SG11201608441YA (en) |
| TW (1) | TWI605048B (en) |
| WO (1) | WO2015199136A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI623316B (en) * | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
| WO2018085833A2 (en) * | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyl transferase 5 (prmt5) |
| WO2018085818A1 (en) * | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018089786A1 (en) * | 2016-11-11 | 2018-05-17 | Millennium Pharmaceuticals, Inc. | Atg7 inhibitors and the uses thereof |
| JP7125714B2 (en) * | 2016-12-13 | 2022-08-25 | ヤマサ醤油株式会社 | 2'-Deoxy-7-deazapurine nucleoside derivatives with antiviral activity |
| CA3087354C (en) * | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN108822145B (en) * | 2018-06-11 | 2020-10-23 | 广东工业大学 | A kind of sulfonamide compound and its preparation method and application |
| CN108640945B (en) * | 2018-06-11 | 2020-10-23 | 广东工业大学 | A kind of amide compound and its preparation method and application |
| EP3820533A2 (en) * | 2018-07-13 | 2021-05-19 | IL-2RX, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02012B (en) * | 2005-02-04 | 2013-02-28 | Millennium Pharm Inc | Inhibitors of e1 activating enzymes |
| WO2007067559A2 (en) * | 2005-12-06 | 2007-06-14 | Regents Of The University Of Minnesota | Antibacterial agents |
| SI1989206T1 (en) | 2006-02-02 | 2012-11-30 | Millennium Pharm Inc | Inhibitors of e1 activating enzyme |
| WO2012061551A1 (en) * | 2010-11-05 | 2012-05-10 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor |
| AU2012204843A1 (en) | 2011-01-07 | 2013-05-02 | Leo Pharma A/S | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| EP2738873A4 (en) * | 2011-07-29 | 2015-04-01 | Kuang Chi Innovative Tech Ltd | Artificial composite material and antenna made of artificial composite material |
| KR101623286B1 (en) * | 2012-01-19 | 2016-05-20 | 다이호야쿠힌고교 가부시키가이샤 | 3,5-disubstituted alkynylbenzene compound and salt thereof |
-
2015
- 2015-06-24 RU RU2016149319A patent/RU2658008C2/en active
- 2015-06-24 SG SG11201608441YA patent/SG11201608441YA/en unknown
- 2015-06-24 MX MX2016015015A patent/MX2016015015A/en active IP Right Grant
- 2015-06-24 WO PCT/JP2015/068218 patent/WO2015199136A1/en active Application Filing
- 2015-06-24 DK DK15811341.5T patent/DK3103802T3/en active
- 2015-06-24 AU AU2015281155A patent/AU2015281155B9/en not_active Ceased
- 2015-06-24 PL PL15811341T patent/PL3103802T3/en unknown
- 2015-06-24 NO NO15811341A patent/NO3103802T3/no unknown
- 2015-06-24 ES ES15811341.5T patent/ES2656772T3/en active Active
- 2015-06-24 JP JP2015555474A patent/JP6192741B2/en not_active Expired - Fee Related
- 2015-06-24 PT PT158113415T patent/PT3103802T/en unknown
- 2015-06-24 US US15/122,863 patent/US9963456B2/en active Active
- 2015-06-24 HU HUE15811341A patent/HUE037266T2/en unknown
- 2015-06-24 TW TW104120451A patent/TWI605048B/en not_active IP Right Cessation
- 2015-06-24 BR BR112016025835-5A patent/BR112016025835B1/en not_active IP Right Cessation
- 2015-06-24 MY MYPI2016704032A patent/MY183327A/en unknown
- 2015-06-24 CN CN201580034466.6A patent/CN106661031B/en not_active Expired - Fee Related
- 2015-06-24 EP EP15811341.5A patent/EP3103802B1/en active Active
- 2015-06-24 CA CA2946833A patent/CA2946833C/en active Active
- 2015-06-24 KR KR1020177002160A patent/KR101947289B1/en not_active Expired - Fee Related
-
2016
- 2016-10-25 PH PH12016502130A patent/PH12016502130A1/en unknown
-
2018
- 2018-02-07 US US15/890,470 patent/US10174040B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264049A (en) | Compounds, compositions, and methods for the treatment of disease | |
| HK1247922A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer | |
| IL264156A (en) | Compounds, compositions, and methods for the treatment of disease | |
| SG11201608441YA (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| EP3533466A4 (en) | Pharmaceutical composition for cancer treatment and/or prevention | |
| PL3065732T3 (en) | Compounds, compositions and uses thereof for the prevention and/or treatment of dyslipidemia | |
| EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
| ZA201707951B (en) | Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases | |
| IL263697A (en) | Compounds, compositions and methods for prevention and/or treatment of cancer | |
| IL263793A (en) | Compounds and compositions for the treatment of cancer | |
| EP3241551A4 (en) | Pharmaceutical composition for treating cancer, containing lactate metal salt | |
| IL275525A (en) | Pharmaceutical composition for the treatment of cancer | |
| HK1232128A1 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| EP3162803A4 (en) | New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient | |
| EP3290051A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| EP3235808A4 (en) | Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same | |
| HK1249044A1 (en) | Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases | |
| EP3677267A4 (en) | Pharmaceutical composition for tumor treatment or prevention, method, and use thereof | |
| IL252487B (en) | Arylalkylamine compounds for use in the prevention or treatment of cancer | |
| EP3372233A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| PL3236961T3 (en) | Pharmaceutical composition for preventing or treating cancer | |
| EP3219323B8 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis c | |
| EP3388067A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| EP3326631A4 (en) | Compound pac-1 or salt thereof, and pharmaceutical composition comprising same |